Danaher Corporation

CEO Rainer M. Blair has overseen Life Sciences scale‑up and the Veralto separation, with DBS embedded across the enterprise. The Rales brothers remain deeply involved at the board level and are significant beneficial owners, aligning governance with long‑term value.

A planned CFO transition to Matthew Gugino in February 2026 appears orderly and consistent with Danaher’s deep bench. Culture, process discipline and owner orientation are evident in disclosures and operating cadence.